D-0258-2025 Class III

Recalled by Kowa Pharmaceuticals America — Montgomery, AL

FDA drug recall D-0258-2025 was initiated by Kowa Pharmaceuticals America on Feb 24, 2025 and is designated Class III. Reason for recall: Presence of foreign tablets/capsules Affected quantity: 5,328 Bottles.

Recall details

Product Type
Drugs
Report Date
Mar 19, 2025
Initiation Date
Feb 24, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,328 Bottles

Product description

Livalo (pitavatstatin) tablets, 4 mg, 90-count bottles, Rx only, Manufactured by: Patheon, Inc. Cincinnati, OH 45237 USA or by Kowa Company, Ltd, Nagoya, 462-0024 Japan, Marketed by Kowa Pharmaceuticals: Kowa Pharmaceuticals America Inc., Montgomery, AL 36117 USA NDC 66869-404-90 HDPE Bottle, congregated into a shrink wrapped 6-pack further congregated into 24 6-packs in a cardboard case

Reason for recall

Presence of foreign tablets/capsules

Distribution pattern

PA, OH, and TX

Code information

Lot#: 3231300, Exp 8/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0258-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0258-2025. Report a data issue: hello@regdatalab.com.